WHAT IS CLAIMED IS:

1. A composition of matter selected from the group consisting of:

a) a substantially pure or recombinant FDF03 protein or peptide exhibiting at least about 85% sequence identity over a length of at least about 12 amino acids to a mature polypeptide from SEQ ID NO: 2 or 4;

b) a natural sequence FDF03 of SEQ ID NO: 2 or 4;

c) a fusion protein comprising FDF03 sequence;

d) a substantially pure or recombinant YE01 protein or peptide exhibiting at least about 85% sequence identity over a length of at least about 12 amino acids to a mature polypeptide from SEQ ID NO: 6, 8, or 10;

e) a natural sequence YE01 of SEQ ID NO: 6, 8, or 10;

f) a fusion protein comprising YE01 sequence;

g) a substantially pure or recombinant KTE03 protein or peptide exhibiting at least about 85% sequence identity over a length of at least about 12 amino acids to SEQ ID NO: 12, 14, 16, 18, 20, or 22;

h) a natural sequence KTE03 of SEQ ID NO: 12, 14, 16, 18, 20, or 22; and

i) a fusion protein comprising KTE03 sequence.

2. A substantially pure or isolated protein comprising a segment exhibiting sequence identity to a corresponding portion of a FDF03, YE01, or KTE03 of Claim 1, wherein:

a) said homology is at least about 90% identity and said portion is at least about 9 amino acids;

b) said homology is at least about 80% identity and said portion is at least about 17 amino acids; or

c) said homology is at least about 70% identity and said portion is at least about 25 amino acids.

3. The composition of matter of Claim 1, wherein said:

a) FDF03 comprises a mature sequence of Table 1;

b) YE01 comprises a mature sequence of Table 2;

c) KTE03 comprises a mature sequence of Table 3;

d) protein or peptide:

i) is from a warm blooded animal selected from a mammal, including a primate or rodent;

ii) comprises at least one polypeptide segment of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, or 22;

iii) exhibits a plurality of portions exhibiting said identity;

iv) is a natural allelic variant of FDF03, YE01, or KTE03;

v) has a length at least about 30 amino acids;

vi) exhibits at least two non-overlapping epitopes which are specific for a mammalian FDF03, YE01, or KTE03;

vii) exhibits a sequence identity at least about 90% over a length of at least about 20 amino acids to a rodent FDF03, YE01, or KTE03;

viii) exhibits at least two non-overlapping epitopes which are specific for a primate FDF03, YE01, or KTE03;

ix) exhibits a sequence identity at least about 90% over a length of at least about 20 amino acids to a primate FDF03, YE01, or KTE03;

x) is glycosylated;

xi) has a molecular weight of at least 7 kD with natural glycosylation;

xii) is a synthetic polypeptide;

xiii) is attached to a solid substrate;

xiv) is conjugated to another chemical moiety;

xv) is a 5-fold or less substitution from natural sequence; or

xvi) is a deletion or insertion variant from a natural sequence.

4. A composition comprising:

a) a sterile FDF03 protein or peptide of Claim 1;

b) said FDF03 protein or peptide of Claim 1 and a carrier, wherein said carrier is:

i) an aqueous compound, including water, saline, and/or buffer; and/or

ii) formulated for oral, rectal, nasal, topical, or parenteral administration;

c) a sterile YE01 protein or peptide of Claim 1;

d) said YE01 protein or peptide of Claim 1 and a carrier, wherein said carrier is:

i) an aqueous compound, including water, saline, and/or buffer; and/or

ii) formulated for oral, rectal, nasal, topical, or parenteral administration;

e) a sterile KTE03 protein or peptide of Claim 1; or

f) said KTE03 protein or peptide of Claim 1 and a carrier, wherein said carrier is:

i) an aqueous compound, including water, saline, and/or buffer; and/or

ii) formulated for oral, rectal, nasal, topical, or parenteral administration.

5.. The fusion protein of Claim 1, comprising:

a) mature protein sequence of Table 1, 2, or 3;

b) a detection or purification tag, including a FLAG, His6, or Ig sequence; or

c) sequence of another cell surface protein.

6. A kit comprising a protein or polypeptide of Claim 1, and:

a) a compartment comprising said protein or polypeptide; and/or

b) instructions for use or disposal of reagents in said kit.

7. A binding compound comprising an antigen binding portion from an antibody, which specifically binds to a natural FDF03, YE01, or KTE03 protein of Claim 1, wherein:

a) said protein is a rodent protein;

b) said binding compound is an Fv, Fab, or Fab2 fragment;

c) said binding compound is conjugated to another chemical moiety; or

d) said antibody:

i) is raised against a peptide sequence of a mature polypeptide of Table 1, 2, or 3;

ii) is raised against a mature FDF03, YE01, or KTE03;

iii) is raised to a purified FDF03, YE01, or KTE03;

iv) is immunoselected;

v) is a polyclonal antibody;

vi) binds to a denatured FDF03, YE01, or KTE03;

vii) exhibits a Kd to antigen of at least 30 μM;

viii) is attached to a solid substrate, including a bead or plastic membrane;

ix) is in a sterile composition; or

x) is detectably labeled, including a radioactive or fluorescent label.

8. A kit comprising said binding compound of Claim 7, and:

a) a compartment comprising said binding compound; and/or

b) instructions for use or disposal of reagents in said kit.

9. The kit of Claim 8 capable of making a qualitative or quantitative analysis.

10. A composition comprising:

a) a sterile binding compound of Claim 7; or

b) said binding compound of Claim 7 and a carrier, wherein said carrier is:

i) an aqueous compound, including water, saline, and/or buffer; and/or

ii) formulated for oral, rectal, nasal, topical, or parenteral administration.

11. An isolated or recombinant nucleic acid encoding a protein or peptide or fusion protein of Claim 1, wherein:

a) said protein is from a mammal, including a primate; or

b) said nucleic acid:

i) encodes an antigenic peptide sequence of Table 1, 2, or 3;

ii) encodes a plurality of antigenic peptide sequences of Table 1, 2, or 3;

iii) exhibits at least about 80% identity to a natural cDNA encoding said segment;

iv) is an expression vector;

v) further comprises an origin of replication;

vi) is from a natural source;

vii) comprises a detectable label;

viii) comprises synthetic nucleotide sequence;

ix) is less than 6 kb, preferably less than 3 kb;

x) is from a mammal, including a primate;

xi) comprises a natural full length coding sequence;

xii) is a hybridization probe for a gene encoding said protein; or

xiii) is a PCR primer, PCR product, or mutagenesis primer.

12. A cell or tissue comprising a recombinant nucleic acid of Claim 11.

13. The cell of Claim 12, wherein said cell is:

a) a prokaryotic cell;
b) a eukaryotic cell;
c) a bacterial cell;
d) a yeast cell;
e) an insect cell;
f) a mammalian cell;
g) a mouse cell;
h) a primate cell; or
i) a human cell.

14. A kit comprising said nucleic acid of Claim 11, and:

a) a compartment comprising said nucleic acid;
b) a compartment further comprising a FDF03, YE01, or KTE03 protein or polypeptide; and/or
b) instructions for use or disposal of reagents in said kit.

15. The kit of Claim 14 capable of making a qualitative or quantitative analysis.

16. A nucleic acid which:

a) hybridizes under wash conditions of 30° C and less than 2M salt to the coding portion from SEQ ID NO: 1 or 3;
b) hybridizes under wash conditions of 30° C and less than 2 M salt to the coding portion from SEQ ID NO: 5, 7, or 9;
c) hybridizes under wash conditions of 30° C and less than 2M salt to the coding portion from SEQ ID NO: 11, 13, 15, 17, 19, or 21;

d) exhibits at least about 85% identity over a stretch of at least about 30 nucleotides to a primate FDF03;

e) exhibits at least about 85% identity over a stretch of at least about 30 nucleotides to a primate YE01; or

f) exhibits at least about 85% identity over a stretch of at least about 30 nucleotides to a primate KTE03.

17. The nucleic acid of Claim 16, wherein:

a) said wash conditions are at 45° C and/or 500 mM salt; or

b) said identity is at least 90% and/or said stretch is at least 55 nucleotides.

18. The nucleic acid of Claim 17, wherein:

a) said wash conditions are at 55° C and/or 150 mM salt; or

b) said identity is at least 95% and/or said stretch is at least 75 nucleotides.

19. A method of modulating physiology or development of a cell or tissue culture cell comprising contacting said cell with an agonist or antagonist of a FDF03, YE01, or KTE03.

20. The method of Claim 19, wherein the cell is a leukocyte, and the antagonist is to YE01 and is a monoclonal antibody which binds to DLAIR-1.